Stay updated with breaking news from Relapsing Remitting Multiple. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Nach Fingolimod, Siponimod und Ozanimod ist nun der vierte Sphingosin-1-Phosphat-Rezeptor-Modulator auf dem Markt. Ponesimod ist zugelassen bei Patienten m...
(0) The pivotal Phase 3 OPTIMUM trial showed treatment with ponesimod led to a 30.5 percent reduction in annual relapse rate (p1 The OPTIMUM trial is the first of its kind to compare head-to-head two oral disease modifying treatments (DMTs) in RMS Approval follows more than 10 years of cumulative data from Phase 2 and Phase 3 studies demonstrating ponesimod's efficacy and safety 1,2,3 Approval builds on Janssen's deep-rooted history in neuroscience and reinforces Company commitment to addressing unmet needs for neurological conditions like MS Janssen, the Pharmaceutical Companies of Johnson J...
It started with blurry vision and Brogan went to her GP, who referred her to the hospital. She was diagnosed quickly with the condition and Brogan, who is married to Scott and has a five-year-old daughter Adalyn, said: “It felt like someone had put a timer on my quality of life. I suddenly thought I might not be able to do the same things with my daughter.” ADVERTISEMENT The couple researched treatment for the condition and found Haematopoietic Stem Cell Transplantation could help. Brogan has booked the treatment at Clinica Ruiz in Mexico on August 30. The clinic claims that the success o...
A West Cumbrian mum says being diagnosed with multiple sclerosis was like receiving “a death sentence”. Brogan Johnston was left shocked and devastated when MRI scans found that she had a form of MS called Relapsing Remitting Multiple Sclerosis. MS has no cure and is a lifelong condition that affects the nerves, spinal cord, and brain. This happens when the body’s immune system mistakenly attacks a healthy part of the body – in this case, it damages and destroys the fatty substance that coats and protects the nerve fibres called the Myelin Sheath. When the Myelin Sheath is being d...
Janssen to Highlight Latest Research on Multiple Sclerosis at ACTRIMS Forum 2021 News provided by Share this article Share this article TITUSVILLE, N.J., Feb. 24, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that its latest multiple sclerosis (MS) research will be presented at the 2021 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum from February 25-27. Nine Janssen-sponsored data abstracts on MS research will be presented, including real-world evidence highlighting the impact of fatigue in U.S. adults with ...